石四藥集團(02005.HK)擬5500萬元收購滄州臨港友誼化工全部股權
格隆匯3月9日丨石四藥集團(02005.HK)發佈公吿,2022年3月9日,公司間接全資附屬石家莊四藥有限公司作為買方與賣方(李允、晏利及李姚芝)及目標公司(即滄州臨港友誼化工有限公司)訂立收購協議,據此賣方已同意出售目標公司的全部股權,總代價為人民幣5500萬元。
目標公司由李允、晏利及李姚芝分別持有36%、32%及32%股權。目標公司主要從事甲胺的生產銷售業務,而甲胺是生產咖啡因的主要原材料之一。
公吿表示,目標公司主要從事甲胺的生產銷售業務,而甲胺是生產咖啡因的主要原材料之一。目前,集團生產咖啡因的部分原材料自目標公司採購。公司認為,收購事項能夠保障相關原材料供應及品質的穩定,從而進一步降低集團的原材料成本。董事局預計,作為垂直整合,收購事項將在集團與目標公司的間產生協同效應。此外,目標公司向獨立於公司的中國各類醫藥及化工企業銷售甲胺。考慮到中國甲胺市場的過往表現及未來前景,集團對收購目標公司的日後發展及長期回報持樂觀態度。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.